In a post-hoc analysis of the Wegener Granulomatosis Etanercept Trial (WGET) trial in which patients with GPA were randomized to conventional therapy (cyclophosphamide or methotrexate) or conventional therapy plus etanercept (35), PR3-ANCA titers correlated with disease activity and both PR3- and MPO-ANCA titers decreased during remission induction (36). The gene discussed is MPO; the disease is granulomatosis with polyangiitis.